当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
The Lancet ( IF 168.9 ) Pub Date : 2017-11-01 , DOI: 10.1016/s2213-8587(17)30308-x
Paresh Dandona , Chantal Mathieu , Moshe Phillip , Lars Hansen , Steven C Griffen , Diethelm Tschöpe , Fredrik Thorén , John Xu , Anna Maria Langkilde , Joseph Proietto , Stephen Stranks , Roger Chen , David O'Neal , Alexia Pape , Mark Forbes , Claire Morbey , Anton Luger , Ursula Hanusch , Christoph Schnack , Evelyn Fliesser-Goerzer , Bertram Hoelzl , Christoph Ebenbichler , Rudolf Prager , Luc Van Gaal , Chris Vercammen , Andre Scheen , Chantal Mathieu , Francis Duyck , Frank Nobels , Johannes Ruige , Naresh Aggarwal , Vincent Woo , Bruno St-Pierre , Richard Dumas , Irene Hramiak , Thomas Elliott , Troels Krarup Hansen , Jan Erik Henriksen , Jeppe Gram , Aina Lihn , Jens Bruun , Juha Saltevo , Jyrki Taurio , Jorma Strand , Timo Valle , Sakari Nieminen , Kirsi Pietilainen , Bruno Guerci , Samy Hadjadj , Bertrand Cariou , Bruno Verges , Sophie Borot , Alfred Penfornis , Thomas Schaum , Diethelm Tschoepe , Cornelia Marck , Thomas Horacek , Ludger Rose , Gerhard Klausmann , Joerg Luedemann , Steffi Appelt , Ulrich Aigner , Rolf Goebel , Thomas Behnke , Anette-Gabriele Ziegler , Eva Peterfai , Zsuzsanna Kerenyi , Tamas Oroszlan , Gyula G. Kiss , Laszlo Konyves , Gyorgyi Piros , Moshe Phillip , Ofri Mosenzon , Naim Shehadeh , Faiad Adawi , Julio Wainstein , Francesco Dotta , Piermarco Piatti , Stefano Genovese , Agostino Consoli , Paolo Di Bartolo , Edoardo Mannucci , Carla Giordano , Annunziata Lapolla , Carlos Aguilar , Alberto Esteban , Bazzoni Ruiz , Guillermo Mondragon Ramirez , Emilia Pelayo Orozco , Carlos Alejandro , Stobschinski de Alba , Carlos Medina Pech , Jose Garza Ruiz , Leobardo Sauque Reyna , Guillermo Llamas Esperon , Luis Alejandro Nevarez Ruiz , Maricela Vidrio Velazquez , Fernando Flores Lozano , Jose Gerardo Gonzalez Gonzalez , Pedro Alberto Garcia-Hernandez , Roberto Araujo-Silva , Efrain Villeda - Espinosa , Cristina Mistodie , Daniela Popescu , Ciprian Constantin , Alina Nicolau , Bogdan Popa , Romulus Timar , Cristian Serafinceanu , Ella Pintilei , Alfonso Soto , Margarita Gimenez , Juan Francisco Merino-Torres , Cristobal Morales , Pedro Mezquita , Johan Jendle , Bengt-Olov Tengmark , Jan Eriksson , Magnus Londahl , Bjorn Eliasson , Anthony Gunstone , Simon Heller , Ken Darzy , Peter Mansell , Melanie Davies , Rory Reed , Duncan Browne , Hamish Courtney , Wayne Turner , Mark Blagden , Rory McCrimmon , Richard Bergenstal , Wendy Lane , Kathryn Lucas , Alexander White , Shichun Bao , Judith White , Curtis Jantzi , Neda Rasouli , William Ervin , Lorena Lewy-Alterbaum , Yehuda Handelsman , Bresta Miranda-Palma , Alan Cleland , Raymond Fink , Helena Rodbard , Samer Nakhle , Craig Greenberg , Alan Schorr , Harold Bays , Debra Simmons , Eric Klein , Laurie Kane , Norman Fishman , Eli Ipp , Satish Garg , Anuj Bhargava , Michelle Zaniewski Singh , Julio Rosenstock , James Thrasher , Mark Warren , Laura Young , Vanita Aroda , Jeremy Pettus , David Liljenquist , Robert Busch , Paresh Dandona , Jonathan Wise , David Kayne , William Biggs

Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes.

中文翻译:

达格列净治疗1型糖尿病(DEPICT-1)的患者的疗效和安全性:多中心,双盲,3期,随机对照试验的结果为24周。

达格列净是一种批准用于治疗2型糖尿病的钠-葡萄糖共转运蛋白2抑制剂。我们旨在评估dapagliflozin作为1型糖尿病控制不足的患者中可调节胰岛素的补充剂的疗效和安全性。
更新日期:2017-09-14
down
wechat
bug